BioSpace News Archive

ACELYRIN, INC. today announced its global Phase 2b/3 clinical trial of izokibep in psoriatic arthritis (PsA) met the primary endpoint of ACR50 at week 16 with high statistical significance.

Daxor Corporation, the global leader in blood volume measurement technology announces the expansion of blood volume analysis in three new hospitals through new analyzer purchases, and the utilization of Daxor’s ezBVA Lab service.

Synnovation Therapeutics today announced that the first patient has been dosed in a Phase I trial evaluating SNV1521 in patients with solid tumors.

NRx Pharmaceuticals and HOPE Therapeutics aim to provide highest quality product available to those in need and assure ongoing supply Important step toward goal of providing full suite of supply options, to to provide IV Ketamine to patients and clinics across the country, subject to board approval.

Chromocell Therapeutics Corp. today announced Frank Knuettel, CEO, will present and host one-on-one meetings with investors at the Sidoti March Virtual Investor Conference, taking place on March 13-14, 2024.

Imugene Limited (ASX: IMU), a clinical stage immuno-oncology company, is pleased to announce that its Phase 1 clinical trial of CD19 oncolytic virotherapy drug candidate onCARlytics (on-CAR-19, CF33-CD19 HOV4) has cleared its first cohort within the intratumoral monotherapy arm of the study and is therefore ready to commence combination dosing solid tumour patients with CD19 targeting drug blinatumomab (Blincyto® marketed by Amgen).

Scryb Inc. (CSE: SCYB) (OTC Pink: SCYRF) (FSE: EIY) (“Scryb’’ or the “Company”) is pleased to announce the appointment of Yoav Raiter to its Board of Directors, effective immediately. Yoav remains the Chief Executive Officer of Scryb.

The Jackson Laboratory and LG AI Research signed a partnership agreement creating an alliance between JAX’s longstanding expertise in biomedical research and data analysis and LG’s AI research and product development prowess.

Crinetics Pharmaceuticals, Inc. announced that on March 10, 2024, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 42,450 shares of its common stock to five new non-executive employees under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan.

Rhythm Pharmaceuticals, Inc. announced that on March 6, 2024, the Compensation Committee of Rhythm’s board of directors granted inducement equity grants covering an aggregate of 13,780 shares of its common stock to three new employees, consisting of inducement stock options to purchase an aggregate of 9,180 shares of common stock and inducement restricted stock units, or RSUs, covering an aggregate of 4,600 shares of its common stock.